Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Louise Smith
Observed names:
L Smith,
Louise Koller-Smith,
Louise Koller‐Smith,
Smith, Louise
Institutions:
The University of Queensland,
John Hunter Hospital,
University of Newcastle Australia
Observed institutions:
Griffith University,
The University of Sydney,
Translational Research Institute,
The University of Queensland,
Royal North Shore Hospital,
John Hunter Hospital,
Princess Alexandra Hospital,
University of Florida,
Daniel den Hoed Kliniek,
University of Newcastle Australia
show all 10
ORCID:
0000-0002-3213-4770
Observed ORCID:
0000-0002-3213-4770
OpenAlex ID:
A5111953573
Rheumatoid arthritis synovium contains plasmacytoid dendritic cells
2005
·
Lois L Cavanagh
, Amanda Boyce
, et al.
·
Arthritis Research & Therapy
·
128
PDF
Alterations in gene expression and activity during squamous cell carcinoma development.
2002
·
Magdalena M Serewko
, Claudia Popa
, et al.
·
PubMed
·
124
Inactivation of Glutathione Peroxidase Activity Contributes to UV-Induced Squamous Cell Carcinoma Formation
2007
·
Jennifer Walshe
, Magdalena M. Serewko-Auret
, et al.
·
Cancer Research
·
77
PDF
The SH2 domain-containing protein tyrosine phosphatase SHP-1 is induced by granulocyte colony-stimulating factor (G-CSF) and modulates signaling from the G-CSF receptor
2000
·
AC Ward
, SPMA Oomen
, et al.
·
Leukemia
·
51
Rheumatoid arthritis is a preventable disease: 11 ways to reduce your patients' risk
2022
·
Louise Koller‐Smith
, Ahmed M. Mehdi
, et al.
·
Internal Medicine Journal
·
43
CD62L as a Therapeutic Target in Chronic Lymphocytic Leukemia
2013
·
Melinda Burgess
, Devinder Gill
, et al.
·
Clinical Cancer Research
·
37
E2F Modulates Keratinocyte Squamous Differentiation
2003
·
Chung Fai Wong
, Liam M. Barnes
, et al.
·
Journal of Biological Chemistry
·
34
PDF
E2F suppression and Sp1 overexpression are sufficient to induce the differentiation-specific marker, transglutaminase type 1, in a squamous cell carcinoma cell line
2005
·
Chung Fai Wong
, Liam M Barnes
, et al.
·
Oncogene
·
32
AP-2 transcription factor family member expression, activity, and regulation in human epidermal keratinocytes in vitro
2004
·
Claudia Popa
, Alison L. Dahler
, et al.
·
Differentiation
·
18
Loss of E2F7 Expression Is an Early Event in Squamous Differentiation and Causes Derepression of the Key Differentiation Activator Sp1
2011
·
Mehlika Hazar-Rethinam
, Sarina R. Cameron
, et al.
·
Journal of Investigative Dermatology
·
16
E2F6: a member of the E2F family that does not modulate squamous differentiation
2004
·
Chung Fai Wong
, Liam M. Barnes
, et al.
·
Biochemical and Biophysical Research Communications
·
10
Modulation of proliferation-specific and differentiation-specific markers in human keratinocytes by SMAD7
2004
·
Louise Smith
, Alison L Dahler
, et al.
·
Experimental Cell Research
·
8
A novel method to monitor rheumatoid arthritis prevalence using hospital and medication databases
2024
·
Louise Koller-Smith
, Ahmed Mehdi
, et al.
·
Arthritis Research & Therapy
·
3
Alterations in Gene Expression Associated with Head and Neck Squamous Cell Carcinoma Development.
2004
·
Magdalena M Serewko-Auret
, Alison L Dahler
, et al.
·
PubMed
·
2
Parity, body mass index, smoking and risk of rheumatoid arthritis: data from the Australian Longitudinal Study on Women’s Health
2026
·
Louise Koller-Smith
, Ahmed Mehdi
, et al.
·
BMC Rheumatology
·
1
PDF
CD62L Expression Is Associated With Chronic Lymphocytic Leukemia (CLL) Cell Survival In Vitro and Represents a Novel Therapeutic Target In CLL
2013
·
Melinda Burgess
, Peter Mollee
, et al.
·
Blood
·
1
Understanding potentially modifiable risk factors for rheumatoid arthritis in Australian women
2026
·
Louise Koller-Smith
Supplementary Table 2 from CD62L as a Therapeutic Target in Chronic Lymphocytic Leukemia
2023
·
Melinda Burgess
, Devinder Gill
, et al.
PDF
Supplementary Figure Legends from CD62L as a Therapeutic Target in Chronic Lymphocytic Leukemia
2023
·
Melinda Burgess
, Devinder Gill
, et al.
Supplementary Figure 3 from CD62L as a Therapeutic Target in Chronic Lymphocytic Leukemia
2023
·
Melinda Burgess
, Devinder Gill
, et al.
Supplementary Figure 1 from CD62L as a Therapeutic Target in Chronic Lymphocytic Leukemia
2023
·
Melinda Burgess
, Devinder Gill
, et al.
Supplementary Figure 2 from CD62L as a Therapeutic Target in Chronic Lymphocytic Leukemia
2023
·
Melinda Burgess
, Devinder Gill
, et al.
Supplementary Table 1 from CD62L as a Therapeutic Target in Chronic Lymphocytic Leukemia
2023
·
Melinda Burgess
, Devinder Gill
, et al.
Data from CD62L as a Therapeutic Target in Chronic Lymphocytic Leukemia
2023
·
Melinda Burgess
, Devinder Gill
, et al.
Data from CD62L as a Therapeutic Target in Chronic Lymphocytic Leukemia
2023
·
Melinda Burgess
, Devinder Gill
, et al.
Show more works
View as search
Works count:
30
Citation count:
585
H-index:
10
I10-index:
11
Year
Topic
Type